Literature DB >> 10593997

Psychological functioning before predictive testing for Huntington's disease: the role of the parental disease, risk perception, and subjective proximity of the disease.

M Decruyenaere1, G Evers-Kiebooms, A Boogaerts, J J Cassiman, T Cloostermans, K Demyttenaere, R Dom, J P Fryns.   

Abstract

BACKGROUND: Psychometric testing of participants in predictive DNA testing for Huntington's disease (HD) has shown that 15% of the subjects at risk for HD had at least mild depression or a high score for general anxiety or both in the pre-test period. The main aim of the study was the delineation of variables associated with pre-test distress of applicants for predictive testing for HD. Based on theoretical considerations, four specific hypotheses were tested regarding the role of (1) the test participant's age at the (perceived) parental onset of HD, (2) the affected parent's sex, (3) the perception of the risk for HD, and (4) the subjective proximity of the disease. Secondly, these four variables were used in multiple regression analyses to select the best predictors of pre- and post-test psychological functioning (one year after the test). Increasing the understanding of pre- and post-test distress is important for developing better counselling and support strategies for test applicants.
METHODS: Data were collected by means of clinical interviews and psychometric questionnaires during the pre- and post-test (one year after the test) counselling sessions for predictive testing for HD.
RESULTS: We found significant associations of the participant's age at the parental onset, the subjective proximity of the disease onset, and the perceived risk with pre-test psychometric measures of psychological functioning. Multiple regression analyses showed that the best predictors of pre-test functioning were the perceived proximity of the disease onset and its interaction with risk perception. Regarding post-test functioning, none of the proposed variables had a unique contribution beyond that accounted for by pre-test psychological functioning.
CONCLUSIONS: Test participants who are close to the perceived age of onset of HD and who have a pessimistic risk perception should be given special attention during pre-test counselling because of their possible negative affective condition at that time. Pre-test psychological measures were the best predictors of post-test distress, irrespective of the test result. Suggestions for future longitudinal research are formulated. This kind of research should enable clinical geneticists and mental health professionals to refine the pre- and post-test counselling strategies for predictive DNA testing, not only for HD, but also for other incurable late onset disorders.

Entities:  

Mesh:

Year:  1999        PMID: 10593997      PMCID: PMC1734269     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  39 in total

1.  Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners.

Authors:  A Tibben; R Timman; E C Bannink; H J Duivenvoorden
Journal:  Health Psychol       Date:  1997-01       Impact factor: 4.267

2.  Psychological consequences of presymptomatic testing for Huntington's disease.

Authors:  A Tibben; R A Roos; M F Niermeijer
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

3.  Psychological consequences of presymptomatic testing for Huntington's disease.

Authors:  G Evers-Kiebooms; M Decruyenaere; J P Fryns; K Demyttenaere
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

4.  The measurement of pessimism: the hopelessness scale.

Authors:  A T Beck; A Weissman; D Lester; L Trexler
Journal:  J Consult Clin Psychol       Date:  1974-12

5.  Life events, social support, and illness.

Authors:  I G Sarason; B R Sarason; E H Potter; M H Antoni
Journal:  Psychosom Med       Date:  1985 Mar-Apr       Impact factor: 4.312

6.  Learned helplessness in humans: critique and reformulation.

Authors:  L Y Abramson; M E Seligman; J D Teasdale
Journal:  J Abnorm Psychol       Date:  1978-02

7.  Predictors of psychological adjustment to genetic testing for Huntington's disease.

Authors:  A M Codori; P R Slavney; C Young; D L Miglioretti; J Brandt
Journal:  Health Psychol       Date:  1997-01       Impact factor: 4.267

8.  Depression and pessimism for the future: biased use of statistically relevant information in predictions for self versus others.

Authors:  L B Alloy; A H Ahrens
Journal:  J Pers Soc Psychol       Date:  1987-02

9.  Huntington's chorea. Its impact on the spouse.

Authors:  M B Hans; A H Koeppen
Journal:  J Nerv Ment Dis       Date:  1980-04       Impact factor: 2.254

10.  Conduct disorder and affective disorder among the offspring of patients with Huntington's disease.

Authors:  S E Folstein; M L Franz; B A Jensen; G A Chase; M F Folstein
Journal:  Psychol Med       Date:  1983-02       Impact factor: 7.723

View more
  9 in total

Review 1.  Methodology in longitudinal studies on psychological effects of predictive DNA testing: a review.

Authors:  R Timman; T Stijnen; A Tibben
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

Review 2.  How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: systematic review.

Authors:  Stephanie Sivell; Glyn Elwyn; Clara L Gaff; Angus J Clarke; Rachel Iredale; Chris Shaw; Joanna Dundon; Hazel Thornton; Adrian Edwards
Journal:  J Genet Couns       Date:  2007-10-30       Impact factor: 2.537

3.  Psychological follow-up of presymptomatic genetic testing for spinocerebellar ataxia type 2 (SCA2) in Cuba.

Authors:  Milena Paneque; Carolina Lemos; Karell Escalona; Lizandra Prieto; Rubén Reynaldo; Mercedes Velázquez; Judith Quevedo; Nieves Santos; Luis Enrique Almaguer; Luis Velázquez; Alda Sousa; Manuela Fleming; Jorge Sequeiros
Journal:  J Genet Couns       Date:  2007-02-23       Impact factor: 2.537

4.  Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement.

Authors:  Gianluigi Forloni; Ignazio Roiter; Vladimiro Artuso; Manuel Marcon; Walter Colesso; Elviana Luban; Ugo Lucca; Mauro Tettamanti; Elisabetta Pupillo; Veronica Redaelli; Francesco Mariuzzo; Giulia Boscolo Buleghin; Alice Mariuzzo; Fabrizio Tagliavini; Roberto Chiesa; Anna Ambrosini
Journal:  Prion       Date:  2022-12       Impact factor: 2.547

5.  Living at risk: the sibling's perspective of early-onset Alzheimer's disease.

Authors:  Karen E Wain; Wendy R Uhlmann; Judith Heidebrink; J Scott Roberts
Journal:  J Genet Couns       Date:  2009-01-09       Impact factor: 2.537

6.  Role of the disease in the psychological impact of pre-symptomatic testing for SCA2 and FAP ATTRV30M: Experience with the disease, kinship and gender of the transmitting parent.

Authors:  Milena Paneque; Carolina Lemos; Alda Sousa; Luis Velázquez; Manuela Fleming; Jorge Sequeiros
Journal:  J Genet Couns       Date:  2009-10       Impact factor: 2.537

Review 7.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

8.  Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia: The IT-DIAfN Protocol.

Authors:  Samantha Galluzzi; Anna Mega; Giuseppe Di Fede; Cristina Muscio; Sara Fascendini; Luisa Benussi; Fabrizio Tagliavini; Giovanni B Frisoni; Emilio Di Maria
Journal:  Alzheimer Dis Assoc Disord       Date:  2022-03-16       Impact factor: 2.357

9.  Risk perception before and after presymptomatic genetic testing for Huntington's disease: Not always what one might expect.

Authors:  Kelsey Stuttgen; Rachel Dvoskin; Juli Bollinger; Allison McCague; Barnett Shpritz; Jason Brandt; Debra Mathews
Journal:  Mol Genet Genomic Med       Date:  2018-11-04       Impact factor: 2.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.